MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
AXSM — Axsome Therapeutics, Inc
NasdaqAxsome Therapeutics, Inc
$179.25
-2.82(-1.55%)
- O
- 182.55
- H
- 182.55
- L
- 175.46
- V
- 981.12K
⏱️ End-of-day dataAs of Oct 2, 2026
Axsome Therapeutics, Inc Statistics
Total Valuation
| Market Cap | $10.22B |
| Enterprise Value | $10.20B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | 52.38M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1,792.50 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -158.08 |
| EV / Sales | n/a |
| EV / EBITDA | -168.93 |
| EV / EBIT | -161.04 |
| EV / FCF | -490.04 |
Financial Position
| Current Ratio | 1.39 |
| Quick Ratio | n/a |
| Debt / Equity | 2.68 |
| Debt / EBITDA | -0.24 |
| Debt / FCF | -0.70 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | -1182.37% |
| Return on Assets (ROA) | -90.44% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-69,775 |
| Employee Count | 925 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | $0 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | +49.45% |
| 50-Day Moving Average | $209.41 |
| 200-Day Moving Average | $199.79 |
| Relative Strength Index (RSI) | 20.33 |
| Average Volume (20 Days) | 716,653 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | $17.65M |
| Operating Income | -$62.77M |
| Pretax Income | -$64.54M |
| Net Income | -$64.54M |
| EBITDA | -$60.40M |
| EBIT | -$63.36M |
| Loss Per Share | $-1.26 |
Balance Sheet
| Cash & Cash Equivalents | $30.51M |
| Total Debt | $14.61M |
| Net Cash | $15.90M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | $5.46M |
| Book Value Per Share | $0.10 |
| Working Capital | $17.20M |
Cash Flow
| Operating Cash Flow | -$28.06M |
| Capital Expenditures | -$121.00K |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -$20.82M |
| FCF Per Share | $-0.40 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | -0.20% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |